REFERENCES
  1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin . 2018;68:394-424.
  2. Sturdza A, Pötter R, Fokdal LU, et al. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiother Oncol . 2016;120:428-433.
  3. McIntyre JB, Wu JS, Craighead PS, et al. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol Oncol . 2013;128:409-414.
  4. Kang S, Kim HS, Seo SS, et al. Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma.Gynecol Oncol . 2007;105:662-666.
  5. Miyasaka Y, Yoshimoto Y, Murata K, et al. Treatment outcomes of patients with adenocarcinoma of the uterine cervix after definitive radiotherapy and the prognostic impact of tumor-infiltrating CD8+ lymphocytes in pre-treatment biopsy specimens: a multi-institutional retrospective study. J Radiat Res . 2020;61:275-284.
  6. Kyo S, Kanaya T, Takakura M, et al. A case of cervical cancer with aggressive tumor growth: possible autocrine growth stimulation by G-CSF and Il-6. Gynecol Oncol . 2000;78:383-387.
  7. Matsumoto Y, Mabuchi S, Muraji M, et al. Squamous cell carcinoma of the uterine cervix producing granulocyte colony-stimulating factor: a report of 4 cases and a review of the literature. Int J Gynecol Cancer . 2010;20:417-421.
  8. Connor JP. Aggressive carcinosarcoma of the uterine cervix associated with high levels of granulocyte colony stimulating factor: case report and laboratory correlates. Gynecol Oncol . 2006;103:349-353.
  9. Mabuchi S, Matsumoto Y, Morii E, et al. The first 2 cases of granulocyte colony-stimulating factor producing adenocarcinoma of the uterine cervix. Int J Gynecol Pathol . 2010;29:483-487.
  10. Yabuta M, Takeuchi K, Kitazawa S, et al. Leukocytosis as an initial sign of aggressive growth of granulocyte colony-stimulating factor-producing cervical cancer. Int J Gynaecol Obstet . 2010;111:181-182
  11. Ohkubo Y, Kato S, Kiyohara H, et al. Granulocyte-colony stimulating factor-producing cervical cancers treated with carbon-ion irradiation.J Obstet Gynaecol Res . 2013;39:1111-1115.
  12. Nasu K, Inoue C, Takai N, et al. Squamous cell carcinoma of the cervix producing granulocyte colony-stimulating factor. Obstet Gynecol . 2004;104:1086-1088.
  13. Watanabe A, Wachi T, Omi H, et al. Granulocyte colony-stimulating factor-producing small-cell carcinoma of the uterine cervix: report of a case. Diagn Cytopathol . 2000;23:269-274.
  14. Nakagaki T, Tamura M, Kobashi K, et al. Profiling cancer-related gene mutations in oral squamous cell carcinoma from Japanese patients by targeted amplicon sequencing. Oncotarget . 2017;8:59113-59122.
  15. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature . 2013;499:214-218.
  16. COSMIC | Catalogue of Somatic Mutations in Cancer. https://cancer.sanger.ac.uk/cosmic. Accessed April 1, 2020.
  17. Asano S, Urabe A, Okabe T, et al. Demonstration of granulopoietic factor(s) in the plasma of nude mice transplanted with a human lung cancer and in the tumor tissue. Blood . 1977;49:845-852.
  18. ShimamuraK, Fujimoto J, Hata J, et al. Establishment of specific monoclonal antibodies against recombinant human granulocyte colony-stimulating factor (hG-CSF) and their application for immunoperoxidase staining of paraffin-embedded sections. J Histochem Cytochem . 1990;38:283-286.
  19. Nomura H, Imazeki I, Oheda M, et al. Purification and characterization of human granulocyte colony-stimulating factor (G-CSF). EMBO J . 1986;5:871-876.
  20. Vinh-Hung V, Bourgain C, Vlastos G, et al. Prognostic value of histopathology and trends in cervical cancer: a SEER population study.BMC Cancer . 2007;7:164.
  21. Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis.Lancet Glob Health . 2020;8:e191-e203.
  22. Liu X, Wang W, Meng Q, et al. Extended-field intensity-modulated radiation therapy combined with concurrent chemotherapy for cervical cancer with para-aortic lymph nodes metastasis. Jpn J Clin Oncol . 2019;49:263-269.
  23. Yoon HI, Cha J, Keum KC, et al. Treatment outcomes of extended-field radiation therapy and the effect of concurrent chemotherapy on uterine cervical cancer with para-aortic lymph node metastasis. Radiat Oncol. 2015;10:18.
  24. Sekido Y, Sato M, Usami N, et al. Establishment of a large cell lung cancer cell line (Y-ML-1B) producing granulocyte colony-stimulating factor. Cancer Genet Cytogenet . 2002;137:33-42.
  25. Oshika Y, Nakamura M, Hatanaka H, et al. A human lung cancer xenograft producing granulocyte-colony stimulating factor and parathyroid hormone-related protein. Oncol Rep . 1998;5:359-362.
  26. Tsutsumi H, Yoneshima Y, Ota K, et al. Multiclonality and Radiosensitivity of Granulocyte-colony Stimulating Factor-Producing Lung Adenocarcinoma Positive for an Activating EGFR Mutation.Clin Lung Cancer . 2020;21:e21-e24.
  27. Ojesina AI, Lichtenstein L, Freeman SS, et al. Landscape of genomic alterations in cervical carcinomas. Nature . 2014;506:371-375.
  28. The Cancer Genome Atlas Research Network. Integrated genomic and molecular characterization of cervical cancer. Nature . 2017;543:378-384.
  29. Chatterjee S, Heukamp LC, Siobal M, et al. Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest . 2013;123:1732-1740.
  30. Zhang Y, Kwok-Shing Ng P, Kucherlapati M, et al. A pan-cancer proteogenomic atlas of PI3K/AKT/mTOR pathway alterations. Cancer Cell . 2017;31:820-832.e3.